Management of preterm labor: atosiban or nifedipine?
Author(s) -
Roel de Heus
Publication year - 2010
Publication title -
international journal of women s health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.136
H-Index - 45
ISSN - 1179-1411
DOI - 10.2147/ijwh.s7219
Subject(s) - nifedipine , tocolytic agent , tocolytic , medicine , oxytocin , preterm labour , preterm labor , ritodrine , anesthesia , oxytocin receptor , obstetrics , pregnancy , fetus , gestation , calcium , biology , genetics
Preterm birth is strongly associated with neonatal death and long-term neurological morbidity. The purpose of tocolytic drug administration is to postpone threatening preterm delivery for 48 hours to allow maximal effect of antenatal corticosteroids and maternal transportation to a center with specialized neonatal care facilities. There is uncertainty about the value of atosiban (oxytocin receptor antagonist) and nifedipine (calcium channel blocker) as first-line tocolytic drugs in the management of preterm labor. For nifedipine, concerns have been raised about unproven safety, lack of placebo-controlled trials, and its off-label use. The tocolytic efficacy of atosiban has also been questioned because of a lack of reduction in neonatal morbidity. This review discusses the available evidence, the pros and cons of either drug and aims to provide information to support a balanced choice of first-line tocolytic drug: atosiban or nifedipine?
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom